



BCIL **Biotech Consortium India Limited**

Novel Anti-inflammatory Peptide

TECHNOLOGY AVAILABLE FOR TRANSFER

Presently for treatment of inflammation, steroidal and non-steroidal products are used which have multiple side effects. The present technology inhibits cellular signaling (TLR-4 signaling inhibitors) instead of acting directly against bacterial pathogen.

The current technology being a peptide-based technology,

- ✓ Holds a great promise for the treatment of human and animal diseases because of their high specificity and potency and low incidence of toxicity.
- ✓ This technology can be used as a therapeutic agent against inflammatory disorders (such as sepsis, arthritis and anti-inflammatory drug).


TECHNOLOGY

Experiments in mice model indicates treatment with TB4- BBL2 does not induce any toxicity and the mice can tolerate high concentrations of the peptide (up to 40mg/kg). The peptide treatment suppressed the production of pro-inflammatory cytokines in septicemia.

APPLICATIONS

- The earlier technologies use chemically synthesized pharmaceutical drugs, whereas the current technology uses a cell permeable, therapeutic peptide (Peptide mimetic).
- The technology is revolutionary as it is a novel therapeutic peptide with 29 amino acids.

UNIQUE SELLING PROPOSITION



STAGE OF TECHNOLOGY

- (TRLs 3)- Animal studies based upon mice model have been conducted to show efficacy, toxicity and safety profile

LICENSING OPPORTUNITY

TTO@BCIL is looking for a suitable industrial partner for the development and commercialization of this technology.

CONTACT:

Dr. Purnima Sharma, Managing Director
BIOTECH CONSORTIUM INDIA LIMITED

V Floor, Anuvrat Bhawan, 210, Deen Dayal Upadhyaya Marg,
New Delhi:110002 Phone: +91-11-2321 9064-67

Fax: +91-11-23219063

Email: tto.bcil@biotech.co.in & info.bcil@biotech.co.in

Website: www.biotech.co.in